| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | 0.1 | 0.04 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.092 | 0.06 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.065 | 0.2 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.063 | 0.2 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.054 | 0.2 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | 0.054 | 0.3 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.043 | 0.3 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.037 | 0.4 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | -0.034 | 0.4 |